Safety

Treanda (bendamustine hydrochloride)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

November 2015

Summary View

WARNINGS AND PRECAUTIONS

Infections
  • Patients treated with Treanda are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. Patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation prior to administration

ADVERSE REACTIONS

Postmarketing Experience
  • Cardiovascular disorders: Atrial fibrillation, congestive heart failure (some fatal), myocardial infarction (some fatal), palpitation

 

February 2010

Summary View 

WARNINGS and PRECAUTIONS

Extravasation
  • There are postmarketing reports of bendamustine extravasations resulting in hospitalizations from erythema, marked swelling, and pain. Precautions should be taken to avoid extravasation, including monitoring of the intravenous infusion site for redness, swelling, pain, infection, and necrosis during and after administration of Treanda.

 

Page Last Updated: 12/11/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.